Overview

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Status:
Completed
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal function. The renal function will be calculated by the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.
Phase:
Phase 1
Details
Lead Sponsor:
Zealand Pharma